Nektar Therapeutics (NKTR) vs Tyra Biosciences, Inc. (TYRA)

A side-by-side comparison of Nektar Therapeutics and Tyra Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — NKTR vs TYRA

growth of $100 · dividends reinvested · last 5y
NKTR -82.6% (-29.5%/yr)TYRA -19.5% (-4.2%/yr)TYRA compounded faster over this window
050100150Start $10020222023202420252026$17$81
NKTR TYRA

NKTR vs TYRA: by the numbers

  • •TYRA is the larger company ($1.20B vs $1.14B market cap).
  • •Both run net losses; TYRA's is the smaller (0.00% vs -287.84% net margin).

Metrics side by side

Valuation

MetricNKTRTYRA
P/S ratio20.88N/A
P/B ratio1.263.40

Profitability

MetricNKTRTYRA
Gross margin99.36%0.00%
Operating margin-240.38%0.00%
Net margin-287.84%0.00%
ROE-17.40%-42.01%
ROIC-12.53%-44.73%

Growth (annualized)

MetricNKTRTYRA
Revenue CAGR (5Y)-12.34%N/A
Total return CAGR (5Y)-30.33%9.23%

Frequently asked

How have NKTR and TYRA total returns compared?
Over the past 5 years, NKTR delivered -30.33% and TYRA delivered 9.23% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.